Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
GNI Group. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
GNI Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GNI Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare GNI Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare GNI Group's earnings growth to the Germany market average as no estimate data is available.
Unable to compare GNI Group's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if GNI Group is high growth as no earnings estimate data is available.
Unable to determine if GNI Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
GNI Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Ying Luo, Ph.D. is Chairman, Chief Executive Officer and President of Cullgen Inc. Dr. Luo has been the Chief Executive Officer, President and Representative Executive Officer of GNI Group Ltd. since June, 2009. The pre-clinical, clinical and regulatory teams recruited and supervised by him has successfully gained 6 IND approvals and conduct Phase I/II trials in China or US. Under his leadership, GNI Group had its first Class 1 drug Etuary® approved by China FDA in treating IPF in 2011 through expedited review process. Dr. Luo serves as President and Chief Executive Officer of Gene Networks Inc. He serves as the President at GNI USA, Inc. He co-founded Shanghai Genomics, Inc. in 2001 and serves as its General Manager. He served as Chief Operating Officer of GNI Ltd. He served as Chief Executive Officer and President of Shanghai Genomics, Inc. He joined Aviron Company and Clontech Laboratory. He served as Senior Director of Genomics in Rigel Pharmaceuticals before returning to China to found Shanghai Genomics, Inc. Dr. Luo held various positions at Clonetech. He serves as the Chairman of the Board at Shanghai Genomics, Inc. He has been working on protein-protein interaction related functional genomics technologies since 1992 and had many publications. He also holds the titles of Director of Functional Genomics at Chinese National Genome Centers at both Shanghai and Beijing. He is a faculty member of China Genome Center at Shanghai. Dr. Luo serves as an Adjunct Professor at Shanghai Jiaotong University. Dr. Luo is a frequently invited speaker at international biotech conferences and his story was covered on the front page of the Wall Street Journal in 2003. He has been a Director of GNI Group Ltd. since June 2005. and Gene Networks Inc. Later he built a nationwide orphan drug sales network in China. He also engineered several acquisitions for GNI, including Beijing Continent and Berkeley Advanced Biomaterials and investments into other joint ventures. In his career of 30 years, Dr. Luo has co-authored more than 35 research publications and been inventors of more than 16 patents. Dr. Luo completed his undergraduate education at Peking Union Medical College (Peking University) in 1982 and received his Ph.D. in Biomedical Sciences and Molecular Biology from the University of Connecticut Health Center in the U.S. in 1991 and postdoctoral research on HIV at UCSF in 1993.
Insufficient data for Ying to compare compensation growth.
Insufficient data for Ying to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the GNI Group management team is over 5 years, this suggests they are a seasoned and experienced team.
GNI Group Ltd. researches, develops, manufactures, and sells pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. The company provides Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary for the treatment of radiation pneumonitis, which is in pilot study for Phase III clinical trials; Tamibarotene, a product for treating acute promyelocytic leukemia; and F351 that is in Phase II clinical trial for the treatment of liver fibrosis. In addition, the company is developing Etuary for the treatment of diabetic nephropathy and connective tissue disease associated interstitial lung disease; and F573 for acute liver failure and acute-on-chronic liver failure. Further, it is developing diabetic nephropathy; and connective tissue disease associated interstitial lung disease, which are in investigational new drug application stage. GNI Group Ltd. was founded in 2001 and is headquartered in Tokyo, Japan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.